DUBLIN--(BUSINESS WIRE)--The "Poliomyelitis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 11, 5, 4, 3 and 3 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 4, 3 and 1 molecules, respectively.
Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Report Coverage
- Poliomyelitis - Overview
- Poliomyelitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Poliomyelitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Poliomyelitis - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Bharat Biotech Ltd
- Biken Co Ltd
- Bilthoven Biologicals BV
- Biological E Ltd
- Biological Mimetics Inc
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Cleveland BioLabs Inc
- GlaxoSmithKline Plc
- Grifols SA
- Johnson & Johnson
- KM Biologics Co Ltd
- LG Chem Ltd
- Micron Biomedical Inc
- Nanolek
- Panacea Biotec Ltd
- Sanofi Pasteur SA
- Serum Institute of India Ltd
- Shantha Biotechnics Pvt Ltd
- Wuhan Institute of Biological Products Co Ltd
- Poliomyelitis - Drug Profiles
- (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
- (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
- (diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile
- (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
- (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
- BK-1310 - Drug Profile
- CSB-017 - Drug Profile
- immune globulin (human) - Drug Profile
- JNJ-2348 - Drug Profile
- KD-370 - Drug Profile
- LBVC - Drug Profile
- LBVD - Drug Profile
- polio (monovalent) vaccine - Drug Profile
- polio [serotype 2] vaccine - Drug Profile
- polio [serotype 2] vaccine 1 - Drug Profile
- polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
- polio [strain Sabin] vaccine - Drug Profile
- polio [strain Sabin] vaccine - Drug Profile
- polio [strain Sabin] vaccine - Drug Profile
- polio [strain Sabin] vaccine - Drug Profile
- polio vaccine - Drug Profile
- polio vaccine - Drug Profile
- polio vaccine - Drug Profile
- polio vaccine - Drug Profile
- polio vaccine - Drug Profile
- polio vaccine - Drug Profile
- polio vaccine - Drug Profile
- poliomyelitis [serotype PV3] (virus like particles) vaccine - Drug Profile
- poliomyelitis vaccine - Drug Profile
- poliomyelitis vaccine - Drug Profile
- poliomyelitis vaccine - Drug Profile
- poliomyelitis vaccine + rotavirus vaccine - Drug Profile
- SA-702 - Drug Profile
- Poliomyelitis - Dormant Projects
- Poliomyelitis - Discontinued Products
- Poliomyelitis - Product Development Milestones
- Featured News & Press Releases
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4wjfs4
